Angiotensin II receptors regulate muscle microvascular recruitment and the delivery of nutrients, oxygen, and insulin to muscle. Although angiotensin type 1 receptor antagonism increases muscle microvascular perfusion and insulin action, angiotensin type 2 receptor blockade markedly restricts muscle microvascular blood volume and decreases muscle delivery of insulin. To examine the effects of direct type 2 receptor stimulation using Compound 21 (C21) on microvascular perfusion, insulin delivery and action, and tissue oxygenation in muscle, overnight-fasted adult male rats were infused with C21 systemically. C21 potently increased microvascular blood volume without altering microvascular flow velocity or blood pressure, resulting in a net increase in microvascular blood flow in muscle. This was associated with a substantial increase in muscle interstitial oxygen saturation and insulin delivery into the skeletal and cardiac muscle. These effects were neutralized by coinfusion of the type 2 receptor antagonist or nitric oxide synthase inhibitor. Superimposing C21 infusion on insulin infusion increased insulin-mediated whole body glucose disposal by 50%. C21 significantly relaxed the preconstricted distal saphenous artery ex vivo. We have concluded that direct type 2 receptor stimulation markedly increases muscle microvascular perfusion through nitric oxide biosynthesis and enhances insulin delivery and action in muscle. These findings provide a physiologic mechanistic insight into type 2 receptor modulation of insulin action and suggest that type 2 receptor agonists might have therapeutic potential in the management of diabetes and its associated complications. (Endocrinology 159: 685-695, 2018) 
T he muscle microvasculature plays a pivotal role in maintaining myocyte health and function by providing a continuous supply of oxygen, nutrients, and hormones, as well as metabolic waste removal. Under normal physiological conditions, the proportion of blood flow distributed between the nutritive route, which is in intimate contact with muscle cells, and the non-nutritive route is tightly regulated to control muscle metabolism and function (1) . Angiotensin II (Ang II), a key component of the renin-angiotensin system, fine tunes vascular tone and tissue perfusion via its vasoconstrictive action on Ang II type 1 receptors (AT 1 Rs) and vasorelaxant effect through Ang II type 2 receptors (AT 2 Rs) (2, 3) . In skeletal muscle, perfusion of the microvasculature is determined by precapillary terminal arterioles (4, 5) . Both AT 1 Rs and AT 2 Rs are present throughout the skeletal muscle microcirculation, including endothelial cells, vascular smooth muscle cells, and other vessel-associated cells (6) . AT 1 R blockade acutely increases muscle microvascular blood flow in both humans (7) and rodents (8) (9) (10) , and systemic infusion of AT 2 R antagonist PD123319 markedly restricts muscle microvascular blood volume and flow (9) .
Ang II also potently regulates insulin action (11) (12) (13) . Ang II induces insulin resistance partly through AT 1 Rmediated reduced form of nicotinamide adenine dinucleotide phosphate oxidase activation and oxidative stress (14, 15) . Given that muscle is a major insulin response tissue and accounts for 70% to 80% of insulinstimulated whole body glucose disposal during insulin infusion (16) and previous evidence has confirmed that increased muscle microvascular perfusion is accompanied by increased muscle delivery and action of insulin (5), we speculated and confirmed that Ang II receptors modulate muscle microvascular and metabolic responses to insulin in vivo (8) . Although AT 2 R blockade decreases muscle insulin delivery and action, AT 1 R antagonism rescues insulin action during lipid infusion via increased muscle insulin delivery (8) (9) (10) .
These findings raise the possibility that selective activation of AT 2 R would have beneficial actions on tissue perfusion and insulin action, because AT 1 R blockade engenders an unopposed stimulation of AT 2 Rs in vivo by endogenous ligand. Also, Compound 21 (C21), a highly selective nonpeptide agonist of AT 2 Rs (17) , has been shown to have a variety of beneficial cardiovascular and insulin sensitizing effects. C21 prevents endothelial inflammation and leukocyte adhesion in vitro and in vivo (18) , prevents renal inflammation in early diabetes (19) , ameliorates streptozotocin-induced diabetes by islet protection (20) , promotes adipocyte differentiation and restores adipocyte size in high-fat/ high-fructose diet-induced insulin resistance (21) , and ameliorates insulin resistance in diabetic mice (22) . Whether C21 specifically exerts a vasodilatory action on the precapillary arterioles to increase muscle perfusion and insulin delivery to, and action in, muscle remains unknown.
In the present study, we used state-of-the-art contrastenhanced ultrasound technology, which uses perflutren lipid microspheres as intravascular tracer to trace the muscle microvascular bed in vivo, combined with the insulin clamp technique to examine the effects of direct activation of AT 2 Rs using C21 on muscle microvascular perfusion, microvascular blood volume, which reflects the microvascular endothelial exchange surface area, and insulin delivery to, and action in, muscle in overnight fasted rats. Our results revealed a distinct, physiological mechanism underpinning the AT 2 R modulation of insulin action in vivo in that C21 markedly increased the muscle microvascular blood volume and insulin delivery and these actions led to increased insulin-stimulated glucose disposal.
Materials and Methods

Determination of C21's vasorelaxant effect on preconstricted small arteries
The distal saphenous artery (#250 mm) was dissected, cleaned of adhering connective tissues, and cut into segments ;2 mm in length. Each segment was mounted in a Multi Myograph System (Danish Myo Technology, Aarhus, Denmark). The organ chamber was filled with 6 mL of physiological salt solution buffer (NaCl 130 mM, KCl 4.7 mM, CaCl 2 1.6 mM, MgSO 4 1.17 mM, KH 2 PO 4 1.18 mM, NaHCO 3 14.9 mM, EDTA 0.026 mM, glucose 5.5 mM; pH 7.4), which was constantly bubbled with 95% oxygen and 5% carbon dioxide and maintained at 37°C. Each ring was stretched initially to 5 mN and then allowed to stabilize at the baseline tone. After preconstriction of the arterial ring with 2 mM phenylephrine, C21 was added to the chamber (final concentration, 100 mM) in the presence or absence of either PD123319 (100 mM) or losartan (10 mM). Changes in the arterial tone were recorded.
Animal preparations and experimental protocols
Overnight-fasted adult male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) weighing 250 to 380 g were studied under one of three protocols. Before the study, the rats were fed standard laboratory chow and water ad libitum and housed at 22°6 2°C on a 12-hour light-dark cycle. The rats were anesthetized with thiobutabarbital 180 mg/kg intraperitoneally (Inactin ® ; Sigma-Aldrich, St. Louis, MO), placed in a supine position on a heating pad to ensure euthermia, and intubated to maintain a patent airway. The carotid artery and jugular vein were cannulated with polyethylene tubing (PE-50; Fisher Scientific, Newark, DE) for arterial blood pressure monitoring, arterial blood sampling, and various infusions.
After a 30-to 45-minute baseline period to ensure hemodynamic stability and a stable level of anesthesia, the baseline microvascular parameters, including microvascular blood volume (MBV), microvascular flow velocity (MFV), and microvascular blood flow (MBF), were determined on the proximal adductor muscle group (adductor magnus and semimembranosus) of the right hindlimb using contrast-enhanced ultrasonography (CEU) with microbubbles as the contrast agent (Definity; Lantheus Medical Imaging, North Billerica, MA), as previously described (23) . The rats then received various intravenous infusions as detailed in the subsequent paragraphs (Fig. 1) .
In protocol 1, C21 (300 ng/kg/min; Vicore Pharma AB, Gothenburg, Sweden) was infused for 120 minutes (range, 0 to 120) in the presence or absence of the AT 2 R antagonist PD123319 (50 mg/kg/min) or nitric oxide (NO) synthase inhibitor N G -nitro-L-arginine methyl ester (L-NAME; 50 mg/kg/ min; Sigma-Aldrich). The PD123319 and L-NAME infusion were started 30 minutes before beginning the C21 infusion. At the doses selected, PD123319 potently restricts MBV in muscle (8, 9) and L-NAME increases the mean arterial blood pressure (MAP) by 20 to 30 mm Hg greater than the baseline without affecting the heart rate (9, 24, 25) or muscle MBV (9, 26) . We chose to infuse C21 at 300 ng/kg/min because, at this dose, C21 lowers the MAP in spontaneously hypertensive rats but not in normotensive rats (27) . The microvascular parameters were measured at 0, 30, 60, and 120 minutes using CEU.
In protocol 2, C21 (300 ng/kg/min) or saline (10 mL/min) was infused for 150 minutes (range, 230 to 120) in the presence or absence of PD123319 (50 mg/kg/min) or L-NAME (50 mg/kg/ min) with a hyperinsulinemic euglycemic clamp (3 mU/kg/min) superimposed on the last 120 minutes (range, 0 to 120). The microvascular parameters were measured at 230, 0, 30, 60, and 120 minutes using CEU. At the end of each study in protocols 1 and 2, the rats were killed by an anesthetic overdose, and the gastrocnemius muscle and heart were freeze-clamped in liquid nitrogen for later measurement of Akt phosphorylation using Western blot analysis.
In protocol 3, the rats received a continuous infusion of either saline (10 mL/min) or C21 (300 ng/kg/min) for 30 minutes. At 25 minutes, each rat received a bolus intravenous injection of 1.5 mCi 125 I-insulin (PerkinElmer Inc., Boston, MA). At the end of the study, the rats were killed, and plasma, gastrocnemius, and heart were obtained for determination of muscle 125 I-insulin delivery. Throughout the study, the MAP was monitored via a sensor connected to the intra-arterial catheter (Harvard Apparatus, Holliston, MA; and AD Instruments, Inc., Colorado Springs, CO). During the insulin clamp, the arterial blood glucose was measured every 10 minutes using an Accu-Chek Advantage glucometer (Roche Diagnostics, Indianapolis, IN), and 30% dextrose (30% weight-to-volume ratio) was infused at a variable rate to maintain the blood glucose level within 10% of basal. The study conformed to the Guide for the Care and Use of Laboratory Animals from the National Institutes of Health (publication no. 85-23; revised 1996). The University of Virginia animal care and use committee approved the study protocols.
Determination of protein phosphorylation
Skeletal and cardiac muscle Akt phosphorylation was determined by Western blot analysis, as described previously (8, 28). Primary antibodies against phosphorylated Akt (Ser 473 ) and total Akt were obtained from Cell Signaling Technology (Beverly, MA). All blots were developed using enhanced chemiluminescence (GE Healthcare Bio-Sciences). Chemiluminescence blot images were captured using the UVP imaging system and quantified using ImageQuant, version 3.3, software (GE Healthcare Life Sciences). Both the total and the phosphorylation-specific densities were quantified and the ratios of phosphorylation-specific to total protein density calculated.
Measurement of muscle interstitial oxygen saturation
Muscle interstitial oxygen saturation was measured using a fiberoptic oxygen measurement system (OXYMICRO; World Precision Instruments), based on the effect of dynamic luminescence quenching by molecular oxygen. In brief, a needle housing the fiberoptic oxygen microsensor was inserted into the right hindlimb skeletal muscle, and the glass fiber with its oxygen sensitive tip inside the needle was extended into the muscle interstitium by carefully pressing the syringe plunger. Measurements were taken every 10 seconds, and the 30-minute average values were calculated.
Muscle 125 I-insulin delivery
Five minutes after an intravenous bolus injection of 1.5 mCi 125 I-insulin, the rats were killed. The dose and exposure time were selected because this tracer amount of 125 I-insulin does not increase systemic insulin concentrations and intact insulin has a short circulating half-life (,5 minutes) (29) . A plasma sample was collected, and each rat was then flushed with 120 mL ice-cold saline (10 mL/min) via the carotid artery catheter. The right hindlimb gastrocnemius muscle and heart were collected. Protein-bound 125 I in plasma and muscle samples was precipitated with 30% trichloroacetic acid, and radioactivity was measured using a gamma counter. The results are expressed as disintegrations per minute/g dry weight/5 minutes.
Statistical analysis
All data are presented as the mean 6 standard error of the mean. The statistical analyses were performed with SigmaStat, version 11.0, software (Systat Software, Inc.), using either the Student t test or analysis of variance with post hoc analysis, as appropriate. A P value of , 0.05 was considered statistically significant.
Results
C21 induces arterial relaxation via direct AT 2 R stimulation
AT 2 R activation engenders a variety of cardiovascular effects, including vasodilation. Although C21, a selective agonist of the AT 2 R, is able to induce vasodilation, the underlying mechanisms remain less straightforward. Previous studies have demonstrated both AT 2 Rdependent and AT 2 R-independent mechanisms (30) . As such, we first examined whether C21 causes vasodilation in the distal saphenous artery, a small resistance arteriole with a diameter of ,250 mm. C21 dose dependently dilated phenylephrine-preconstricted distal saphenous arteries (P , 0.05; Fig. 2 ). This action was partially blocked by preincubation of the arterial rings with the equimolar AT 2 R antagonist PD123319 (by .50%; P = 0.005) but not with losartan. This confirms that C21 induces vasodilation via the AT 2 R.
C21 recruits skeletal muscle microvasculature via AT 2 Rs, and this action is mediated through NO production
To examine whether C21 exerts a vasorelaxant action on the precapillary arterioles, which control muscle microvascular perfusion (5, 31), we used CEU to measure the three important indexes of the muscle microcirculation (MBV, MFV, and MBF) before and during continuous infusion of C21 in the presence or absence of PD123319 or L-NAME. C21 significantly increased muscle microvascular recruitment by increasing MBV within the first 30 minutes, and this effect lasted for the entire 120-minute infusion period (P , 0.02; Fig. 3) ; however, MFV was not affected. Because MBF is the product of MBV and MFV, the increase in MBV led to a twofold increase in muscle MBF (P , 0.03). These were associated with a substantial, progressive increase in muscle oxygenation (P , 0.001). The increases in MBV, MBF, and muscle oxygenation induced by C21 were all blocked by either PD123319 or L-NAME, suggesting that these effects were mediated via both AT 2 R and NO biosynthesis. Neither the MAP nor the blood glucose levels changed significantly during C21 infusion ( Table 1) . As expected, L-NAME coinfusion increased the MAP by 20 to 30 mm Hg (P # 0.01).
Addition of insulin to C21 infusion further enhanced microvascular recruitment
Knowing that C21 can recruit muscle microvasculature and also that insulin is able to relax precapillary arterioles to increase microvascular perfusion (5, 32), we next examined whether C21 and insulin can enhance each other's microvascular actions in vivo. As expected, insulin alone significantly increased muscle MBV by ;20% to 25% (P , 0.005; Fig. 4 ) without affecting MFV, resulting in a similar increase in MBF (P , 0.04). Although C21 alone promptly increased muscle MBV and MBF within 30 minutes (P , 0.002 for both) without affecting MFV, the addition of insulin to the C21 infusion further increased muscle MBV (P , 0.02) and MBF (P , 0.009) beyond that observed with C21 alone. The C21 and insulin combination did not change the MFV or MAP during the entire procedure.
Effects of C21 on insulin's metabolic actions
As microvascular recruitment is associated with increased insulin action in muscle (5, 33), we assessed the C21 effect on insulin's metabolic actions by calculating the insulin-mediated whole body glucose disposal and insulin-stimulated phosphorylation of muscle Akt, a key signaling molecule in the insulin signaling pathway. C21 infusion increased insulin-stimulated whole body glucose disposal by ;50% (P , 0.001), beginning at 20 minutes (P = 0.0003; Fig. 5 ). This effect was not evident at 2 minutes (P = 0.671) or 10 minutes (P = 0.191). Insulin and C21 each enhanced Akt phosphorylation in skeletal muscle, and simultaneous infusion of either PD123319 or L-NAME totally abolished C21-mediated Akt phosphorylation (Fig. 6A) . In cardiac muscle, C21-mediated Akt phosphorylation showed a higher trend but did not reach statistical significance (P = 0.09), and similarly, this trend was also blocked by PD123319 or L-NAME (Fig. 6B) .
Effects of C21 on muscle insulin delivery
Given that C21 increased insulin-mediated glucose disposal and Akt phosphorylation, we hypothesized that it acted via increased muscle delivery of insulin. C21 infusion significantly increased insulin delivery to both skeletal (by ;75%; P = 0.01) and cardiac (by 75%; P = 0.002) muscle without increasing the degradation of insulin (Fig. 7) . Coinfusion with either PD123319 or L-NAME completely abolished C21-induced increases in muscle insulin delivery. lead to either decreased or increased muscle insulin delivery and action, respectively, in rodents (8, 9) . In the present study, we have demonstrated that direct activation of AT 2 Rs with C21 potently increases muscle microvascular perfusion, oxygenation, insulin delivery, and metabolic responses via an AT 2 R-dependent, NOmediated mechanism. Both AT 1 Rs and AT 2 Rs appear to be involved in the regulation of insulin sensitivity in vivo. Ang II via AT 1 R activation directly impairs insulin actions via the reduced form of nicotinamide adenine dinucleotide phosphate oxidase pathway (12, 13, 36) and induces vasoconstriction to reduce muscle microvascular perfusion and insulin delivery (9) . In contrast, previous observations suggest that Ang II also possesses an insulin-sensitizing property because acutely increasing Ang II levels systemically improves insulin-stimulated muscle glucose usage in humans (37) (38) (39) . It was speculated that this increase in insulin sensitivity might be secondary to increased tissue perfusion. This was likely the result of AT 2 R activation, which induces relaxation of the capacitance vessels and resistance arterioles and the microvasculature (9, 40-43) via the bradykinin-NO-cyclic guanosine monophosphate signaling cascade (34, 40, 44, 45) . We, and others, have repeatedly shown that muscle microvasculature critically regulates insulin delivery to, and action in, muscle (5, 46) . Although AT 1 R blockade with losartan increases muscle MBV by threefold and enhances tissue delivery of insulin, AT 2 R antagonism with PD123319 reduces muscle MBV by ;80% and depresses insulin delivery to muscle (8) (9) (10) . Consistent with these previous findings, our present data provide evidence that direct stimulation of AT 2 Rs with C21 potently increases muscle microvascular perfusion, insulin delivery, and insulin action. As AT 2 Rs tend to dimerize with bradykinin B2 receptor (47) or AT 1 Rs (48), whether C21 also affects their dimerized receptors remains unknown. The increased muscle microvascular recruitment and insulin delivery to muscle provide a physiological explanation for the observed increase in insulin-mediated whole body glucose disposal during C21 infusion. It is the insulin concentrations in the muscle interstitium, not in the plasma, that best correlate with insulin's muscle metabolic action and whole body glucose disposal (49) . Factors that are able to recruit microvasculature, such as exercise (23, 50) , AT 1 R blockade (8, 10) , adiponectin (51), ranolazine (28) , glucagon-like peptide-1 (26) , and angiotensin-(1-7) (52), all significantly increase muscle insulin delivery and action. Whether C21 exerts similar actions in insulinresistant states to improve insulin responses remains to be defined. In addition to a sufficient endothelium exchange surface area, reflected by the MBV, insulin delivery into the muscle interstitium also involves transendothelial transport of insulin (5, 46) . Whether this process is affected by C21 remains to be examined.
Discussion
The muscle microvasculature supplies tissue with oxygen to meet tissue metabolic needs. Reduced tissue perfusion results in tissue hypoxia, which contributes to the pathogenesis of insulin resistance (53) and tissue dysfunction. We have previously shown that expansion of the muscle microvasculature by either insulin or AT 1 R blockade with losartan markedly increases muscle interstitial oxygen saturation in rats (8) . As AT 1 R blockade results in unopposed stimulation of AT 2 Rs in vivo, it is possible that the previous observation of losartan to increase tissue oxygenation is a result of AT 2 R activation, which was confirmed by the present study. Whether a combination of an AT 1 R blocker and an AT 2 R activator will further enhance tissue oxygenation, in particular, in insulin-resistant states, remains to be studied. This is important for patients with diabetes and obesity owing to their propensity to develop arthrosclerosis with decreased tissue perfusion. Modulation of the relative activities of AT 1 Rs and AT 2 Rs might provide a therapeutic target to alleviate the resulting organ dysfunction and damage. This certainly warrants further investigation.
Our observations that the addition of insulin to C21 further increased microvascular recruitment is not surprising because insulin (54) and AT 2 R activation each trigger vasorelaxation via distinctly different, but both NO-dependent, signaling pathways. Higher NO production, such as is seen in the case of glucagon-like peptide-1 or losartan administration (8, 10, 26) , can increase MBV by two-to threefold. Given that both pathways are NOdependent and the curvilinear quantification of microbubble signals used by CEU, it is not possible to use the currently available technology to quantitatively separate the effects produced by insulin from those produced by C21 in the muscle microvasculature.
The mechanism underlying C21-stimulated Akt phosphorylation observed in the present study remains to be defined. Although activation of AT 2 R has been linked to Akt phosphorylation (55), our results suggest that this is likely secondary to increased delivery of insulin to muscle, which then subsequently stimulates Akt phosphorylation. That both PD123319 and L-NAME were able to abolish the C21-mediated increase in Akt phosphorylation strongly suggests that AT 2 R-mediated vascular action plays a critical role in C21-mediated Akt phosphorylation.
It is interesting that in the ex vivo myograph study, C21 induced arteriolar relaxation and this effect was only partially abolished by PD123319, but in the in vivo microvascular perfusion study, C21-induced microvascular recruitment was completely prevented by PD123319, along with the associated increase in muscle interstitial oxygenation. Indeed, previous in vitro studies have shown that C21 at high concentrations (100 to 1000 mM) induces both constriction (via AT 1 R) and vasodilation (by blocking calcium transport into the cell) (30) . The vasodilatory effect of this very high concentration of C21 did not appear to be AT 2 R dependent because PD123319 did not block it. Another explanation is that because C21 and PD123319 appear to have similar binding affinity to the AT 2 R (30) and we used equimolar concentrations for both C21 and PD123319, partial blockade would be expected. At lower concentrations (1 to 10 mM), C21 evokes only vasodilation, and this effect was blocked by PD123319 (27) . With a molecular weight of 475.63 g/mol and the assumption of a blood volume of ;20 mL in a 300-g rat (56), the maximal blood concentration of C21 would be ;4 mM at 30 minutes and ;12 mM at 120 minutes (assuming that no degradation occurred). This is much lower than the concentrations achieved in the ex vivo study. Thus, it is likely that at lower concentrations, C21 induces vasodilation via AT 2 Rs and at very high concentrations, it also stimulates AT 1 Rs and blocks calcium transport into the cell. This could also explain the discrepancy that the vasodilatory action of very high concentrations of C21 observed in vitro was not inhibited by L-NAME (30); however, in our study, L-NAME abolished C-21-induced increases in MBV and insulin-stimulated glucose disposal in vivo.
Conclusion
Muscle microvasculature provides an endothelial exchange surface area that critically regulates the muscle delivery of nutrients, oxygen, and insulin. We have previously shown that AT 1 Rs and AT 2 Rs differentially regulate muscle microvascular perfusion and insulin action. Our present results have demonstrated, to the best of our knowledge, for the first time, that direct stimulation of the AT 2 Rs markedly recruits muscle microvasculature via NO biosynthesis, which expands the microvascular exchange surface area, improves muscle oxygenation, and enhances insulin delivery and metabolic action in muscle. As numerous clinical trials have demonstrated that AT 1 R blockade (which decreases AT 1 R activity and also engenders unopposed stimulation of the AT 2 R in vivo) significantly reduces newonset diabetes, in addition to lowering blood pressure (11), AT 2 R agonism holds therapeutic potential in the prevention and treatment of diabetes and its associated complications. Whether the present results will remain valid after longterm use of C21 warrants further investigation.
Acknowledgments
Financial Support: This work was supported by National Institutes of Health Grants R01HL094722 and R01DK102359 (to Z.L.) and Natural Science Foundation of China Grant 81300657 (to N.W.).
Author Contributions: F.Y., Z.Y., N.W., K.W.A., and Z.L. researched data. R.M.C., L.C., and X.Z. contributed to the discussion. Z.L. wrote the manuscript.
Appendix. Antibody Table   Peptide 
